BACKGROUND: We aimed to develop multiple single-nucleotide polymorphism (SNP)-based risk models associated with the risk of transplant outcomes including graft-versus-host disease (GVHD). METHODS: The study evaluated 259 SNPs in 53 genes in 394 pairs of donors and recipients. In a discovery set (n=307 receiving related donor transplantation), overall survival, relapse-free survival (RFS), nonrelapse mortality, and acute or chronic GVHD were evaluated. RESULTS: Eight recipients' SNPs of IL2, IL6R, FAS, EDN1, TGFB1, and NFKBIA genes and 12 donors' SNPs of NOS1, IL1B, TGFB2, NOD2/CARD15, TNFRII, IL1R1, and FCGR2A genes were identified in univariate analyses. Risk models were generated using significant clinical variables and genetic SNP markers after filtering out through multivariate analyses. Then, we divided patients into four quartiles (25%, Q) according to their risks. The final models stratified patients into low-risk (Q1), moderate-risk (Q2, Q3), and high-risk (Q4) groups in terms of overall survival (P<0.0001), RFS (P<0.0001), nonrelapse mortality (P=0.0043), and acute GVHD (P<0.0001), but not for chronic GVHD (P=0.763). External validation was performed in 87 transplant pairs that received matched unrelated donor transplantation, especially for RFS (P=0.016) and acute GVHD (P=0.027). CONCLUSION: Risk models can improve prognostic stratification of patients according to their risk for transplant outcome.
BACKGROUND: We aimed to develop multiple single-nucleotide polymorphism (SNP)-based risk models associated with the risk of transplant outcomes including graft-versus-host disease (GVHD). METHODS: The study evaluated 259 SNPs in 53 genes in 394 pairs of donors and recipients. In a discovery set (n=307 receiving related donor transplantation), overall survival, relapse-free survival (RFS), nonrelapse mortality, and acute or chronic GVHD were evaluated. RESULTS: Eight recipients' SNPs of IL2, IL6R, FAS, EDN1, TGFB1, and NFKBIA genes and 12 donors' SNPs of NOS1, IL1B, TGFB2, NOD2/CARD15, TNFRII, IL1R1, and FCGR2A genes were identified in univariate analyses. Risk models were generated using significant clinical variables and genetic SNP markers after filtering out through multivariate analyses. Then, we divided patients into four quartiles (25%, Q) according to their risks. The final models stratified patients into low-risk (Q1), moderate-risk (Q2, Q3), and high-risk (Q4) groups in terms of overall survival (P<0.0001), RFS (P<0.0001), nonrelapse mortality (P=0.0043), and acute GVHD (P<0.0001), but not for chronic GVHD (P=0.763). External validation was performed in 87 transplant pairs that received matched unrelated donor transplantation, especially for RFS (P=0.016) and acute GVHD (P=0.027). CONCLUSION: Risk models can improve prognostic stratification of patients according to their risk for transplant outcome.
Authors: Ezgi Karaesmen; Abbas A Rizvi; Leah M Preus; Philip L McCarthy; Marcelo C Pasquini; Kenan Onel; Xiaochun Zhu; Stephen Spellman; Christopher A Haiman; Daniel O Stram; Loreall Pooler; Xin Sheng; Qianqian Zhu; Li Yan; Qian Liu; Qiang Hu; Amy Webb; Guy Brock; Alyssa I Clay-Gilmour; Sebastiano Battaglia; David Tritchler; Song Liu; Theresa Hahn; Lara E Sucheston-Campbell Journal: Blood Date: 2017-08-15 Impact factor: 22.113
Authors: N Alam; W Xu; E G Atenafu; J Uhm; M Seftel; V Gupta; J Kuruvilla; J H Lipton; H A Messner; D D H Kim Journal: Bone Marrow Transplant Date: 2015-03-16 Impact factor: 5.483
Authors: Carolina Martínez-Laperche; Elena Buces; M Carmen Aguilera-Morillo; Antoni Picornell; Milagros González-Rivera; Rosa Lillo; Nazly Santos; Beatriz Martín-Antonio; Vicent Guillem; José B Nieto; Marcos González; Rafael de la Cámara; Salut Brunet; Antonio Jiménez-Velasco; Ildefonso Espigado; Carlos Vallejo; Antonia Sampol; José María Bellón; David Serrano; Mi Kwon; Jorge Gayoso; Pascual Balsalobre; Álvaro Urbano-Izpizua; Carlos Solano; David Gallardo; José Luis Díez-Martín; Juan Romo; Ismael Buño Journal: Blood Adv Date: 2018-07-24
Authors: D Kim; H-H Won; S Su; L Cheng; W Xu; N Hamad; J Uhm; V Gupta; J Kuruvilla; H A Messner; J H Lipton Journal: Bone Marrow Transplant Date: 2014-03-03 Impact factor: 5.483
Authors: Paul J Martin; Wenhong Fan; Barry E Storer; David M Levine; Lue Ping Zhao; Edus H Warren; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Michael Boeckh; Sangeeta Hingorani; Li Yan; Qiang Hu; Leah Preus; Song Liu; Stephen Spellman; Xiaochun Zhu; Marcelo Pasquini; Philip McCarthy; Daniel Stram; Xin Sheng; Loreall Pooler; Christopher A Haiman; Lara Sucheston-Campbell; Theresa Hahn; John A Hansen Journal: Blood Date: 2016-10-06 Impact factor: 22.113
Authors: Esteban Arrieta-Bolaños; Neema P Mayor; Steven G E Marsh; J Alejandro Madrigal; Jane F Apperley; Keiren Kirkland; Stephen Mackinnon; David I Marks; Grant McQuaker; Julia Perry; Michael N Potter; Nigel H Russell; Kirsty Thomson; Bronwen E Shaw Journal: Haematologica Date: 2015-11-26 Impact factor: 9.941
Authors: Petra Kövy; Nóra Meggyesi; Lívia Varga; Katalin Balassa; András Bors; László Gopcsa; Melinda Paksi; Árpád Bátai; Eszter Vad; János Sinkó; Attila Tordai; Tamás Masszi; Péter Reményi; Hajnalka Andrikovics Journal: Bone Marrow Transplant Date: 2019-09-16 Impact factor: 5.483
Authors: Marc Ansari; Kateryna Petrykey; Mohamed Aziz Rezgui; Veronica Del Vecchio; Jacques Cortyl; Milad Ameur; Tiago Nava; Patrick Beaulieu; Pascal St-Onge; Simona Jurkovic Mlakar; Chakradhara Rao S Uppugunduri; Yves Théoret; Imke H Bartelink; Jaap-Jan Boelens; Robbert G M Bredius; Jean-Hugues Dalle; Victor Lewis; Bill S Kangarloo; Selim Corbacioglu; Daniel Sinnett; Henrique Bittencourt; Maja Krajinovic Journal: Bone Marrow Transplant Date: 2021-07-02 Impact factor: 5.174